CRH is said to near $8 billion deal for Arcosa (CRH:NYSE)
CRH is reportedly near an $8 billion deal to acquire Arcosa (ACA), a deal that would represent a significant premium to Arcosa's recent market cap. The setup pits Arcosa as a near-certain takeover target against CRH absorbing material acquisition risk at a stretched multiple.
What happened
CRH is reportedly near an $8 billion deal to acquire Arcosa (ACA), a deal that would represent a significant premium to Arcosa's recent market cap.
The read · Jun 21
With CRH reportedly near an $8B deal for Arcosa (ACA), the question is whether the deal closes at or near the rumored price and whether CRH's stock absorbs a meaningful M&A discount for the acquisition premium.
Wrong if
Deal falls through or terms are materially different from the $8B figure — ACA collapses back to pre-rumor levels and CRH recovers, punishing both legs of the pair.
CoverageSource: Seeking Alpha · Published here SUN, JUN 21 · 4:42 PM ET · the only report in this recordHow this is decided →
The chart · ACATradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
CRH, the Irish-listed building materials giant with $37.4B in revenue, is reportedly closing in on an $8 billion acquisition of Arcosa (ACA), a construction products and infrastructure materials company generating $1.5B in revenue with strong 28.7% YoY growth. An $8B price tag implies a roughly 5x revenue multiple on Arcosa — steep but partially justified by Arcosa's 48.6% gross margins and accelerating top-line growth. The deal would mark a major bolt-on for CRH as it deepens its U.S. infrastructure exposure, aligning with the ongoing IIJA-driven construction cycle.
The immediate setup is a classic M&A binary: Arcosa shares should trade toward the deal price if confirmed, while CRH faces the market's judgment on whether it's overpaying. Watch for an official announcement — at $8B, this is a CRH board-level decision requiring shareholder scrutiny — and monitor whether competing bids emerge given Arcosa's attractive margin profile and infrastructure tailwinds.
The read, in fullWhy it matters
Classic M&A pair: long ACA to capture spread to deal value, short CRH to hedge acquirer dilution risk. Arcosa's 48.6% gross margins and 28.7% revenue growth justify strategic interest but an ~5x revenue multiple is rich by building-materials standards. CRH already runs at 10.1% net margins and adding $8B in debt or equity to a $37.4B revenue base is non-trivial — acquirers routinely sell off 2-5% on deal announcement.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written
Next · what would move this
1-3 weeks, into deal confirmation. Follow to be told when one lands.
▲ The case it holds
Arcosa's accelerating revenue growth (+28.7% YoY), high gross margins (48.6%), and direct exposure to IIJA infrastructure spending make it a genuinely scarce asset that justifies a premium, supporting ACA shares trading toward or above the $8B implied price — especially if a competing bid surfaces.
▼ The case it breaks
At an implied ~5x revenue multiple, CRH may be overpaying for a sub-$2B revenue business, and with CRH's own net margins at 10.1%, the deal is immediately dilutive to returns on capital, leaving CRH shares vulnerable to a meaningful selloff on confirmation.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →